Noubar Afeyan has started 76 companies over his career. One of those companies is Moderna, the COVID vaccine maker that recently surpassed Merck in market value. Afeyan discusses Moderna’s success and where his firm m, Flagship Pioneering, is looking for its next opportunity.See <a href="https://omnystudio.com/listener">omnystudio.com/listener</a> for privacy information.

Noubar Afeyan has started 76 companies over his career. One of those companies is Moderna, the COVID vaccine maker that recently surpassed Merck in market value. Afeyan discusses Moderna’s success and where his firm m, Flagship Pioneering, is looking for its next opportunity. See omnystudio.com/listener for privacy information.

Noubar Afeyan has started 76 companies over his career. One of those companies is Moderna, the COVID vaccine maker that recently surpassed Merck in market value. Afeyan discusses Moderna’s success and where his firm m, Flagship Pioneering, is looking for its next opportunity.See <a href="https://omnystudio.com/listener" rel="noopener noreferrer">omnystudio.com/listener</a> for privacy information.

Noubar Afeyan

What makes a great leader? How can leadership be developed into a force for true achievement? The David Rubenstein Show: Peer-to-Peer Conversations explores successful leadership through the personal and professional choices of the most influential people in business. Renowned financier and philanthropist David Rubenstein travels the country talking to leaders to uncover their stories and their path to success. Each episode features an interview with one business leader.

Share Noubar Afeyan

Sign up to save your podcasts

Noubar Afeyan

Noubar Afeyan

More shows like The David Rubenstein Show

Exchanges

Bloomberg Surveillance

Masters in Business

Odd Lots

Invest Like the Best with Patrick O'Shaughnessy

Capital Allocators – Inside the Institutional Investment Industry

Talks at GS

Value Investing with Legends

Here's Why

Wall Street Week

The Memo by Howard Marks

Business Breakdowns

In Good Company with Nicolai Tangen

The Insight by Oaktree Capital

Bloomberg Talks